The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats
Authors:
Open Access
- 1 November 2014
- journal article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. 8, 2173-9
Abstract
The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats Lu Song,* Xinxin Yang,* Yaping Ma, Na Wu, Zhenguo Liu Department of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, People’s Republic of China *These authors contributed equally to this work The dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA) has been used as an effective drug for treating dopamine depletion-induced Parkinson’s disease (PD). However, long-term administration of L-DOPA produces motor complications. L-DOPA has also been found to modify the two key signaling cascades, protein kinase A/dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) and extracellular signal-regulated kinases 1 and 2 (ERK1/2), in striatal neurons, which are thought to play a pivotal role in forming motor complications. In the present study, we tested the possible effect of a CB1 cannabinoid receptor agonist on L-DOPA-stimulated abnormal behavioral and signaling responses in vivo. Intermittent L-DOPA administration for 3 weeks induced motor fluctuation in a rat model of PD induced by intrastriatal infusion of dopamine-depleting neurotoxin 6-hydroxydopamine (6-OHDA). A single injection of a CB1 cannabinoid receptor agonist WIN-55,212-2 had no effect on L-DOPA-induced motor fluctuation. However, chronic injections of WIN-55,212-2 significantly attenuated abnormal behavioral responses to L-DOPA in 6-OHDA-lesioned rats. Similarly, chronic injections of WIN-55,212-2 influence the L-DOPA-induced alteration of DARPP-32 and ERK1/2 phosphorylation status in striatal neurons. These data provide evidence for the active involvement of CB1 cannabinoid receptors in the regulation of L-DOPA action during PD therapy. Keywords: striatum, the CB1 receptor agonist WIN-55,212-2, 6-hydroxydopamine, Parkinson’s disease, motor fluctuation, L-DOPAKeywords
This publication has 36 references indexed in Scilit:
- Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptorsNeurobiology of Aging, 2011
- Spatiotemporal Pattern of Striatal ERK1/2 Phosphorylation in a Rat Model of L-DOPA–Induced Dyskinesia and the Role of Dopamine D1 ReceptorsBiological Psychiatry, 2007
- Role of Cannabinoid Type 1 Receptors in Locomotor Activity and Striatal Signaling in Response to PsychostimulantsJournal of Neuroscience, 2007
- Critical Involvement of cAMP/DARPP-32 and Extracellular Signal-Regulated Protein Kinase Signaling in L-DOPA-Induced DyskinesiaThe Journal of Neuroscience, 2007
- Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian ratsBrain, 2007
- Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: Effect on adenosine A2AreceptorsSynapse, 2006
- ERK Phosphorylation and FosB Expression Are Associated with L-DOPA-Induced Dyskinesia in Hemiparkinsonian MiceBiological Psychiatry, 2006
- Cannabinoid Action Depends on Phosphorylation of Dopamine- and cAMP-Regulated Phosphoprotein of 32 kDa at the Protein Kinase A Site in Striatal Projection NeuronsJournal of Neuroscience, 2005
- Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian ratsExperimental Neurology, 2005
- Differential expression of protein phosphatase 1 isoforms in mammalian brainJournal of Neuroscience, 1995